JP2020526525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526525A5 JP2020526525A5 JP2020500617A JP2020500617A JP2020526525A5 JP 2020526525 A5 JP2020526525 A5 JP 2020526525A5 JP 2020500617 A JP2020500617 A JP 2020500617A JP 2020500617 A JP2020500617 A JP 2020500617A JP 2020526525 A5 JP2020526525 A5 JP 2020526525A5
- Authority
- JP
- Japan
- Prior art keywords
- rvwf
- medicament according
- bleeding
- subject
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims description 14
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims description 14
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 10
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 10
- 208000032843 Hemorrhage Diseases 0.000 claims description 8
- 230000000740 bleeding effect Effects 0.000 claims description 8
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 5
- 102100036537 von Willebrand factor Human genes 0.000 claims description 5
- 229960001134 von willebrand factor Drugs 0.000 claims description 5
- 108010054218 Factor VIII Proteins 0.000 claims description 4
- 102000001690 Factor VIII Human genes 0.000 claims description 4
- 208000027276 Von Willebrand disease Diseases 0.000 claims description 4
- 229960000301 factor viii Drugs 0.000 claims description 4
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 208000010287 Type 3 von Willebrand Disease Diseases 0.000 claims description 2
- 208000020294 von Willebrand disease 1 Diseases 0.000 claims description 2
- 208000017129 von Willebrand disease 2 Diseases 0.000 claims description 2
- 208000015316 von Willebrand disease 3 Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 20
- 229940079593 drug Drugs 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 5
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023106554A JP7641327B2 (ja) | 2017-07-07 | 2023-06-29 | 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530027P | 2017-07-07 | 2017-07-07 | |
| US62/530,027 | 2017-07-07 | ||
| PCT/US2018/041320 WO2019010497A1 (en) | 2017-07-07 | 2018-07-09 | TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023106554A Division JP7641327B2 (ja) | 2017-07-07 | 2023-06-29 | 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526525A JP2020526525A (ja) | 2020-08-31 |
| JP2020526525A5 true JP2020526525A5 (enExample) | 2021-08-12 |
| JP7307047B2 JP7307047B2 (ja) | 2023-07-11 |
Family
ID=63036433
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500617A Active JP7307047B2 (ja) | 2017-07-07 | 2018-07-09 | 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 |
| JP2023106554A Active JP7641327B2 (ja) | 2017-07-07 | 2023-06-29 | 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023106554A Active JP7641327B2 (ja) | 2017-07-07 | 2023-06-29 | 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10632176B2 (enExample) |
| EP (2) | EP3648788B1 (enExample) |
| JP (2) | JP7307047B2 (enExample) |
| KR (1) | KR20200037235A (enExample) |
| CN (1) | CN111436193A (enExample) |
| AU (2) | AU2018298233B2 (enExample) |
| BR (1) | BR112020000321A2 (enExample) |
| CA (1) | CA3069295A1 (enExample) |
| CO (1) | CO2020001322A2 (enExample) |
| DK (1) | DK3648788T3 (enExample) |
| ES (1) | ES2986574T3 (enExample) |
| FI (1) | FI3648788T5 (enExample) |
| PL (1) | PL3648788T3 (enExample) |
| PT (1) | PT3648788T (enExample) |
| WO (1) | WO2019010497A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018298233B2 (en) | 2017-07-07 | 2025-04-24 | Takeda Pharmaceutical Company Limited | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF |
| CA3128498A1 (en) | 2019-02-01 | 2020-08-06 | Bjorn Mellgard | Methods of prophylactic treatment using recombinant vwf (rvwf) |
| US20220395560A1 (en) * | 2019-02-01 | 2022-12-15 | Takeda Pharmaceutical Company Limited | METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) |
| EP4013389A1 (en) * | 2019-08-16 | 2022-06-22 | Octapharma AG | Stabilizing buffer for factor viii and vwf |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US8597910B1 (en) | 1985-04-11 | 2013-12-03 | Children's Medical Center Corporation | DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells |
| WO1986006096A1 (en) | 1985-04-11 | 1986-10-23 | The Children's Medical Center Corporation | Von willebrand factor |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| US6005077A (en) | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
| AT403764B (de) | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| AT405403B (de) | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| AT405485B (de) | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| AU2003291689A1 (en) | 2002-10-31 | 2004-05-25 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
| WO2005012354A1 (en) | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
| EP1593388A1 (en) | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| PL1835938T3 (pl) | 2004-12-27 | 2014-01-31 | Baxalta Inc | Koniugaty polimer-czynnik von Willebrandta |
| KR101423344B1 (ko) | 2006-01-04 | 2014-07-30 | 백스터 인터내셔널 인코포레이티드 | 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법 |
| DK2167117T3 (da) | 2007-06-13 | 2012-11-19 | Csl Behring Gmbh | Anvendelse af VWF-stabiliserede FVIII-præparater til ekstravaskulær administration til terapeutisk og profylaktisk behandling af blødningsforstyrrelser |
| EP2222329A1 (en) | 2007-11-09 | 2010-09-01 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
| AU2008345135C1 (en) | 2007-12-28 | 2015-04-30 | Takeda Pharmaceutical Company Limited | Recombinant VWF formulations |
| AU2009262476C1 (en) | 2008-06-24 | 2016-06-02 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
| CN103919736A (zh) | 2008-10-21 | 2014-07-16 | 巴克斯特国际公司 | 冻干的重组vwf配方 |
| JP2013500743A (ja) | 2009-08-04 | 2013-01-10 | バクスター・インターナショナル・インコーポレイテッド | Ｆｖｉｉｉおよびｖｗｆがノックアウトされた遺伝子導入マウス−血友病ａモデル |
| CN103097522A (zh) | 2010-07-08 | 2013-05-08 | 巴克斯特国际公司 | 在细胞培养物中生产重组adamts13的方法 |
| EP3858375B1 (en) * | 2011-06-10 | 2024-03-20 | Takeda Pharmaceutical Company Limited | Treatment of coagulation disease by administration of recombinant vwf |
| CN107406493B (zh) | 2015-03-06 | 2021-08-13 | 康诺贝林伦瑙有限公司 | 具有改善的半衰期的经修饰的血管性血友病因子 |
| AU2018298233B2 (en) | 2017-07-07 | 2025-04-24 | Takeda Pharmaceutical Company Limited | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF |
-
2018
- 2018-07-09 AU AU2018298233A patent/AU2018298233B2/en active Active
- 2018-07-09 FI FIEP18746458.1T patent/FI3648788T5/fi active
- 2018-07-09 EP EP18746458.1A patent/EP3648788B1/en active Active
- 2018-07-09 JP JP2020500617A patent/JP7307047B2/ja active Active
- 2018-07-09 EP EP24176324.2A patent/EP4424366A3/en active Pending
- 2018-07-09 BR BR112020000321-2A patent/BR112020000321A2/pt unknown
- 2018-07-09 KR KR1020207003264A patent/KR20200037235A/ko active Pending
- 2018-07-09 US US16/030,659 patent/US10632176B2/en active Active
- 2018-07-09 CA CA3069295A patent/CA3069295A1/en active Pending
- 2018-07-09 PL PL18746458.1T patent/PL3648788T3/pl unknown
- 2018-07-09 ES ES18746458T patent/ES2986574T3/es active Active
- 2018-07-09 WO PCT/US2018/041320 patent/WO2019010497A1/en not_active Ceased
- 2018-07-09 PT PT187464581T patent/PT3648788T/pt unknown
- 2018-07-09 CN CN201880057599.9A patent/CN111436193A/zh active Pending
- 2018-07-09 DK DK18746458.1T patent/DK3648788T3/da active
-
2020
- 2020-02-06 CO CONC2020/0001322A patent/CO2020001322A2/es unknown
- 2020-02-26 US US16/802,118 patent/US10905746B2/en active Active
- 2020-12-01 US US17/108,562 patent/US11529395B2/en active Active
-
2022
- 2022-12-06 US US18/062,534 patent/US12016904B2/en active Active
-
2023
- 2023-06-29 JP JP2023106554A patent/JP7641327B2/ja active Active
-
2024
- 2024-06-12 US US18/741,650 patent/US20240316160A1/en active Pending
-
2025
- 2025-07-11 AU AU2025205392A patent/AU2025205392A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Erhan et al. | Ondansetron, granisetron, and dexamethasone compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: A randomized placebo-controlled study | |
| Mulier et al. | A randomized controlled, double-blind trial evaluating the effect of opioid-free versus opioid general anaesthesia on postoperative pain and discomfort measured by the QoR-40 | |
| Obayah et al. | Addition of dexmedetomidine to bupivacaine for greater palatine nerve block prolongs postoperative analgesia after cleft palate repair | |
| Nesek-Adam et al. | Comparison of dexamethasone, metoclopramide, and their combination in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy | |
| JP2020526525A5 (enExample) | ||
| JP2016074740A5 (enExample) | ||
| Skolnik et al. | Update on the management of postoperative nausea and vomiting | |
| JP2019529541A5 (enExample) | ||
| Storms et al. | Effectiveness of azelastine nasal solution in seasonal allergic rhinitis | |
| BR112013010829B1 (pt) | Omposição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| Kundra et al. | Comparative study of epidural application of morphine versus gelfoam soaked in morphine for lumbar laminectomy | |
| Godoy et al. | Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome? | |
| Shadangi et al. | A prospective, randomized, double-blind, comparative study of the efficacy of intravenous ondansetron and palonosetron for prevention of postoperative nausea and vomiting | |
| FI3648788T3 (fi) | Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää | |
| Dadmehr et al. | Is preemptive oral tizanidine effective on postoperative pain intensity after bimaxillary orthognathic surgery? A triple-blind randomized clinical trial | |
| Tan et al. | Intravenous infusion of lidocaine enhances the efficacy of conventional treatment of postherpetic neuralgia | |
| Li et al. | Remifentanil is superior to propofol for treating emergence agitation in adults after general anesthesia | |
| JP2009524612A (ja) | 多発性硬化症を治療及び／又は予防するための方法、ならびに多発性硬化症の間欠的治療用及び／又は間欠的予防用の薬剤を製造するためのエリスロポエチンの使用 | |
| Bhandage et al. | Evaluation of efficacy of peri-operative administration of hydrocortisone and dexamethasone in prevention of post-operative complications in oral and maxillofacial surgeries | |
| Pongchairerks et al. | Metoclopramide, versus its combination with dexamethasone in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a double-blind randomized controlled trial | |
| Banerjee et al. | PONV in Ambulatory surgery: A comparison between Ramosetron and Ondansetron: a prospective, double-blinded, and randomized controlled study | |
| El Shal | A comparative study of effect of intravenous lidocaine infusion, gabapentin and their combination on postoperative analgesia after thyroid surgery | |
| Entezariasl et al. | Efficacy of metoclopramide and dexamethasone for postoperative nausea and vomiting: a double-blind clinical trial | |
| Chen et al. | Dexamethasone effectively reduces postoperative nausea and vomiting in a general surgical adult patient population | |
| FLJJII et al. | Effective dose of granisetron in the reduction of nausea and vomiting after breast surgery |